DES MOINES, Iowa, May 24, 2016 /PRNewswire/ -- In line with an increased commitment to expand its presence in the North American market through strategic alignments, Eurofins STA Laboratories, Inc. (ESTA) and Eurofins BioDiagnostics Inc. (EBDI) have merged into a single company and brand. By combining the analytical and genetic service strengths of EBDI with the extensive experience of ESTA in the seed and plant health arena, this new entity becomes the most complete analytical testing company in North America focused on the seed, plant, and agbio testing markets.
The combined company will maintain the name of Eurofins BioDiagnostics. The consolidated portfolio of assays provides an unparalleled suite of testing services for the seed and plant industries, from germination testing to disease resistance screening to grapevine plant disease diagnosis to genetic fingerprinting to testing a wide range of seed pathogens for many different crop species, and many other analytical testing services. In addition, EBDI is a validated partner with many trait providers, utilizing their proprietary methods. These services are tailored to better serve clients' testing needs on a global basis. Laboratory operations will continue to expand in the company's three main locations: River Falls (Wisconsin), Longmont (Colorado), and Gilroy (California). All in all, the services provided by the new EBDI will complement and build onto the recognized capabilities that Eurofins provides to the seed and agricultural industry world-wide and enhance Eurofins' ability to provide the broadest base of support to this important market.
Commenting on the merger, Michael Drozd, President of the Eurofins BioDiagnostics said, "Although there is significant brand recognition and loyalty in the Eurofins STA brand, we believe that the name BioDiagnostics better captures our broader vision for the future of the company. The Eurofins BioDiagnostics brand signifies diagnostic discovery and innovation for the global agricultural biological market. At the same time, our constant commitment to providing the highest level of customer service and quality will not change, and we are excited to be able to serve our valued customers with the most complete offering of services for seed and plant testing in the industry."
For more information, please visit www.eurofinsus.com/biodiagnostics
Notes for the editor:
Eurofins – a global leader in bio-analysis
Eurofins Scientific believes it is the world leader in food, environment and pharmaceutical products testing, as well as one of the global market leaders in agroscience, genomics, discovery pharmacology and central laboratory services. In addition, Eurofins is one of the key emerging players in specialty clinical diagnostic testing in Europe and the USA.
With over 23,000 staff in more than 225 laboratories across 39 countries, Eurofins offers a portfolio of over 130,000 validated analytical methods for evaluating the safety, identity, composition, authenticity, origin, traceability and purity of biological substances and products, as well as for innovative clinical diagnostic. The Group provides its customers with high-quality services, accurate results on time and expert advice by its highly qualified staff.
Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.
As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the expanding demands of regulatory authorities and healthcare practitioners around the world.
The shares of Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).
This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgment of Eurofins Scientific as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the data available to the Company as of the date of publication, but no guarantee can be made as to their validity.
SOURCE Eurofins Scientific